BE2013C074I2 - - Google Patents

Info

Publication number
BE2013C074I2
BE2013C074I2 BE2013C074C BE2013C074C BE2013C074I2 BE 2013C074 I2 BE2013C074 I2 BE 2013C074I2 BE 2013C074 C BE2013C074 C BE 2013C074C BE 2013C074 C BE2013C074 C BE 2013C074C BE 2013C074 I2 BE2013C074 I2 BE 2013C074I2
Authority
BE
Belgium
Application number
BE2013C074C
Other languages
French (fr)
Original Assignee
The Regents Of The Univ Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C074(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Regents Of The Univ Of California filed Critical The Regents Of The Univ Of California
Publication of BE2013C074I2 publication Critical patent/BE2013C074I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
BE2013C074C 2005-05-13 2013-12-18 BE2013C074I2 (enrdf_load_html_response)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68083505P 2005-05-13 2005-05-13
US75035105P 2005-12-15 2005-12-15
US75655206P 2006-01-06 2006-01-06

Publications (1)

Publication Number Publication Date
BE2013C074I2 true BE2013C074I2 (enrdf_load_html_response) 2025-09-17

Family

ID=37431537

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C074C BE2013C074I2 (enrdf_load_html_response) 2005-05-13 2013-12-18

Country Status (29)

Country Link
EP (5) EP3106162A1 (enrdf_load_html_response)
JP (12) JP4644737B2 (enrdf_load_html_response)
KR (12) KR101332924B1 (enrdf_load_html_response)
CN (6) CN116003328A (enrdf_load_html_response)
AT (1) ATE541571T1 (enrdf_load_html_response)
AU (1) AU2006248109B2 (enrdf_load_html_response)
BE (1) BE2013C074I2 (enrdf_load_html_response)
BR (1) BRPI0610359B8 (enrdf_load_html_response)
CA (1) CA2608436C (enrdf_load_html_response)
CY (2) CY1112798T1 (enrdf_load_html_response)
DK (2) DK1893196T4 (enrdf_load_html_response)
ES (2) ES2535179T3 (enrdf_load_html_response)
HK (1) HK1217103A1 (enrdf_load_html_response)
HR (2) HRP20120323T4 (enrdf_load_html_response)
HU (1) HUS1300076I1 (enrdf_load_html_response)
IL (3) IL187328A (enrdf_load_html_response)
LU (1) LU92338I2 (enrdf_load_html_response)
ME (1) ME01992B (enrdf_load_html_response)
MX (4) MX394667B (enrdf_load_html_response)
NO (4) NO339997B1 (enrdf_load_html_response)
NZ (3) NZ591119A (enrdf_load_html_response)
PL (2) PL1893196T5 (enrdf_load_html_response)
PT (2) PT2444085E (enrdf_load_html_response)
RS (2) RS52274B2 (enrdf_load_html_response)
RU (3) RU2448096C3 (enrdf_load_html_response)
SG (1) SG10201703816SA (enrdf_load_html_response)
SI (2) SI2444085T1 (enrdf_load_html_response)
WO (1) WO2006124118A1 (enrdf_load_html_response)
ZA (2) ZA200710870B (enrdf_load_html_response)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550447A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
ES2535179T3 (es) * 2005-05-13 2015-05-06 The Regents Of The University Of California Compuesto de diarilhidantoína como antagonistas de los receptores de andrógenos para el tratamiento de cáncer
NZ572335A (en) * 2006-03-27 2011-09-30 Univ California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
NZ596260A (en) * 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
TW200846338A (en) * 2007-02-01 2008-12-01 Chugai Pharmaceutical Co Ltd Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof
US8461343B2 (en) * 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
TWI557111B (zh) * 2007-10-26 2016-11-11 加州大學董事會 二芳基乙內醯脲類化合物
BRPI1007990A2 (pt) * 2009-02-24 2015-09-01 Medivation Prostate Therapeutics Inc Compostos específicos de diaril-hidantoína e diariltioidantoína.
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
EP2430190B1 (en) * 2009-05-12 2018-11-21 Koninklijke Philips N.V. Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer
WO2011029392A1 (en) * 2009-09-10 2011-03-17 Youzhi Tong Androgen receptor antagonists and uses thereof
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
CA2773615A1 (en) 2009-09-11 2011-03-17 Arwed Cleve Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
KR101735675B1 (ko) 2009-12-11 2017-05-15 오티포니 세라피틱스 리미티드 이미다졸리딘디온 유도체
SMT201800277T1 (it) 2010-02-16 2018-07-17 Aragon Pharmaceuticals Inc Modulatori di recettore di androgeni e loro usi
PT3329775T (pt) * 2010-02-24 2021-07-19 Medivation Prostate Therapeutics Llc Processos para a síntese de compostos de diariltiohidantoína e diarilhidantoína
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
CN103328467B (zh) 2010-12-06 2016-08-10 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
AU2012225038B2 (en) * 2011-03-10 2016-03-10 Suzhou Kintor Pharmaceuticals, Inc. Androgen receptor antagonists and uses thereof
EP2699561B1 (en) 2011-04-21 2015-06-03 Orion Corporation Androgen receptor modulating carboxamides
BR112013031402A2 (pt) 2011-06-07 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
EP2739153B1 (en) * 2011-07-29 2018-08-22 Medivation Prostate Therapeutics LLC Treatment of breast cancer
PH12014500943A1 (en) 2011-11-30 2014-06-30 Astrazeneca Ab Combination treatment of cancer
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
WO2013175215A1 (en) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
WO2014036897A1 (zh) * 2012-09-04 2014-03-13 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用
EP3971167A1 (en) * 2012-09-11 2022-03-23 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
US20150239848A1 (en) * 2012-09-11 2015-08-27 Dr. Reddy's Laboratories Limited Enzalutamide polymorphic forms and its preparation
KR20210013342A (ko) 2012-09-26 2021-02-03 아라곤 파마슈티컬스, 인코포레이티드 비전이성 거세 저항성 전립선암 치료용 항안드로겐
US9944607B2 (en) 2012-10-16 2018-04-17 Whitehead Institute For Biomedical Research Thiohydantoin derivatives and uses thereof
EP2911666B1 (en) * 2012-10-26 2022-08-24 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
RU2520134C1 (ru) * 2013-02-27 2014-06-20 Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
BR112015031155A2 (pt) 2013-06-20 2017-07-25 Bayer Cropscience Ag derivados de sulfureto de arila e derivados de aril sulfóxido como acaricidas e inseticidas
WO2015018356A1 (zh) * 2013-08-08 2015-02-12 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
US20160228446A1 (en) * 2013-09-19 2016-08-11 GlaxoSmithKline LLCC Combination Drug Therapy
CN106543085A (zh) * 2013-10-14 2017-03-29 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
WO2015063720A1 (en) 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Process for the preparation of enzalutamide
WO2015092617A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Processes and intermediates for the preparation of enzalutamide
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
EP3105208A1 (en) 2014-02-13 2016-12-21 Ranbaxy Laboratories Limited Process for the preparation of enzalutamide
CZ2014232A3 (cs) 2014-04-07 2015-10-14 Zentiva, K.S. Způsob výroby enzalutamidu
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
CN103910679B (zh) * 2014-04-23 2016-05-25 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
CN104003939B (zh) * 2014-06-06 2017-07-07 山东大学 二芳基取代乙内酰硫脲类化合物及其制备方法与应用
CN104016924B (zh) * 2014-06-16 2016-04-13 上海鼎雅药物化学科技有限公司 一种“一锅法”合成恩杂鲁胺的方法
WO2015196144A2 (en) 2014-06-20 2015-12-23 England Pamela M Androgen receptor antagonists
RU2557235C1 (ru) 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
EP3166931A4 (en) * 2014-07-11 2018-05-09 Shilpa Medicare Limited An improved process for the preparation of enzalutamide
CA2969656A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Solid formulations of arn-509 and hydroxypropyl methylcellulose acetate succinate
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
CN104610111A (zh) * 2014-12-26 2015-05-13 杭州和泽医药科技有限公司 一种4-异硫代氰酰基-2-(三氟甲基)苯甲腈的制备方法
CN105523958B (zh) * 2015-01-13 2017-11-03 北京海步医药科技股份有限公司 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法
CA2974367A1 (en) * 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
ITUB20151204A1 (it) 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151311A1 (it) * 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
WO2016194813A1 (ja) 2015-05-29 2016-12-08 アステラス製薬株式会社 エンザルタミド結晶形の製造方法
KR20180048939A (ko) * 2015-09-10 2018-05-10 지앙수 헨그루이 메디슨 컴퍼니 리미티드 안드로겐 수용체 억제제의 결정체 형태 및 그의 제조 방법
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CA3030184A1 (en) * 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Thiohydantoin androgen receptor antagonists for the treatment of cancer
JP7048106B2 (ja) 2016-12-16 2022-04-05 カンプ・バイオファーマスーティカルズ、リミテッド 組み合わせ、その用途及び処置方法
PL3616696T3 (pl) 2017-04-28 2025-05-05 Astellas Pharma Inc. Kompozycja farmaceytczna do podawania doustnego zawierająca enzalutamid
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
EP3876929A1 (en) 2018-11-05 2021-09-15 Pfizer Inc. Combination for treating cancer
CA3121199A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN109796437B (zh) * 2019-02-26 2021-08-24 上海健康医学院 具有ar和hdac双重抑制作用的乙内酰脲类和乙内酰硫脲类化合物及用途
CA3143111A1 (en) 2019-06-27 2020-12-30 Synthon B.V. Process for preparation of enzalutamide
CN110452166A (zh) * 2019-09-06 2019-11-15 浙江朗华制药有限公司 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法
EP4037659A1 (en) 2019-10-03 2022-08-10 Synthon BV Pharmaceutical composition comprising enzalutamide
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
IL300581A (en) 2020-08-13 2023-04-01 Pfizer Combined treatment
CN116848116A (zh) 2020-12-11 2023-10-03 日东制药株式会社 作为雄激素受体和磷酸二酯酶双重抑制剂的新颖化合物
CA3214316A1 (en) 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
EP4112603A1 (en) 2021-06-29 2023-01-04 Química Sintética, S.A. Processes for the preparation of non-steroidal antiandrogens
US20240288500A1 (en) 2021-10-13 2024-08-29 Lg Energy Solution, Ltd. Battery charge and discharge profile analysis method, and battery charge and discharge profile analysis apparatus
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN117164520B (zh) * 2022-01-28 2025-04-25 南京思聚生物医药有限公司 一种局部作用的雄激素受体拮抗剂及其应用
KR20230170859A (ko) 2022-06-11 2023-12-19 이태영 패스트칫솔
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN115850186B (zh) * 2023-02-07 2024-04-09 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的晶型及用途
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
ZA839023B (en) * 1982-12-06 1985-07-31 Pfizer Spiro-3-hetero-azolones for treatment of diabetic complications
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
CA2181358A1 (en) † 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
FR2741342B1 (fr) * 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
EP1122242B1 (en) 1998-09-22 2008-01-16 Astellas Pharma Inc. Cyanophenyl derivatives
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
EP1546111A2 (fr) 2002-10-04 2005-06-29 Laboratoires Fournier S.A. Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20050005529A1 (en) 2003-07-10 2005-01-13 David Brault Lighting system for a greenhouse
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
JP4989227B2 (ja) * 2004-09-09 2012-08-01 中外製薬株式会社 新規イミダゾリジン誘導体およびその用途
ES2535179T3 (es) * 2005-05-13 2015-05-06 The Regents Of The University Of California Compuesto de diarilhidantoína como antagonistas de los receptores de andrógenos para el tratamiento de cáncer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds

Also Published As

Publication number Publication date
ES2378778T5 (es) 2015-09-25
MX394667B (es) 2025-03-21
AU2006248109B2 (en) 2012-11-15
KR20210136161A (ko) 2021-11-16
NZ591119A (en) 2012-08-31
MX346924B (es) 2017-04-05
RS52274B (en) 2012-10-31
EP1893196B2 (en) 2015-07-29
RU2638833C2 (ru) 2017-12-18
HRP20150437T1 (xx) 2015-06-05
MX2007014132A (es) 2008-04-09
CN116003328A (zh) 2023-04-25
JP5138753B2 (ja) 2013-02-06
ZA200710870B (en) 2012-06-27
KR20140041831A (ko) 2014-04-04
EP1893196A1 (en) 2008-03-05
JP2015098497A (ja) 2015-05-28
CN101222922B (zh) 2012-04-18
NO339997B1 (no) 2017-02-27
JP2019218352A (ja) 2019-12-26
PT1893196E (pt) 2012-04-03
PT2444085E (pt) 2015-06-11
RU2017142159A (ru) 2019-06-05
HK1112856A1 (en) 2008-09-19
JP2016183200A (ja) 2016-10-20
JP6013535B2 (ja) 2016-10-25
BRPI0610359A2 (pt) 2010-06-15
ATE541571T1 (de) 2012-02-15
JP2012236843A (ja) 2012-12-06
JP2018100292A (ja) 2018-06-28
IL187328A (en) 2016-02-29
ES2378778T3 (es) 2012-04-17
HK1217103A1 (zh) 2016-12-23
MX2022009759A (es) 2022-09-05
NO2017019I1 (no) 2017-05-04
WO2006124118A1 (en) 2006-11-23
KR20120102140A (ko) 2012-09-17
KR20080014039A (ko) 2008-02-13
CN102584712A (zh) 2012-07-18
ME01992B (me) 2012-10-30
ES2535179T3 (es) 2015-05-06
KR20110041580A (ko) 2011-04-21
AU2006248109A1 (en) 2006-11-23
JP2023075313A (ja) 2023-05-30
KR102713358B1 (ko) 2024-10-02
KR20190104244A (ko) 2019-09-06
RU2448096C2 (ru) 2012-04-20
EP1893196A4 (en) 2009-03-18
BRPI0610359B1 (pt) 2020-09-24
CY2013047I1 (el) 2015-11-04
KR20130060369A (ko) 2013-06-07
CN120682155A (zh) 2025-09-23
SI2444085T1 (sl) 2015-06-30
JP5150780B2 (ja) 2013-02-27
CY1112798T1 (el) 2015-11-04
JP2012211190A (ja) 2012-11-01
HK1169321A1 (en) 2013-01-25
JP2011068653A (ja) 2011-04-07
KR20140141676A (ko) 2014-12-10
JP2024153705A (ja) 2024-10-29
NO2017019I2 (no) 2017-05-04
HUS1300076I1 (hu) 2013-12-17
SG10201703816SA (en) 2017-06-29
RU2007146462A (ru) 2009-06-20
KR20150086567A (ko) 2015-07-28
CN105037273B (zh) 2019-04-19
NZ564223A (en) 2011-03-31
JP2021035970A (ja) 2021-03-04
DK2444085T3 (en) 2015-04-27
SI1893196T2 (sl) 2015-10-30
IL187328A0 (en) 2008-04-13
LU92338I2 (fr) 2015-10-27
KR101169832B1 (ko) 2012-07-30
JP2022101657A (ja) 2022-07-06
RU2448096C3 (ru) 2017-12-11
EP2444085B1 (en) 2015-03-18
NO342490B1 (no) 2018-06-04
KR101332889B1 (ko) 2013-11-26
CN110003114B (zh) 2023-01-17
NO20161996A1 (no) 2008-02-08
KR101515335B1 (ko) 2015-04-24
IL243812A0 (en) 2016-04-21
CN105037273A (zh) 2015-11-11
KR101782236B1 (ko) 2017-09-26
KR102481886B1 (ko) 2022-12-28
MX2019015200A (es) 2020-02-05
EP2561871A1 (en) 2013-02-27
SI1893196T1 (sl) 2012-06-29
BRPI0610359B8 (pt) 2021-05-25
NO20076401L (no) 2008-02-08
PL2444085T3 (pl) 2015-07-31
CY2013047I2 (el) 2015-11-04
IL258880A (en) 2018-06-28
CN101222922A (zh) 2008-07-16
KR101579701B1 (ko) 2015-12-22
HRP20120323T4 (hr) 2015-10-09
CA2608436A1 (en) 2006-11-23
KR102020721B1 (ko) 2019-09-10
KR101431407B1 (ko) 2014-08-18
KR20230003445A (ko) 2023-01-05
KR102324567B1 (ko) 2021-11-09
HRP20120323T1 (en) 2012-05-31
DK1893196T4 (en) 2015-10-19
ZA201201793B (en) 2015-12-23
PL1893196T5 (pl) 2015-12-31
DK1893196T3 (da) 2012-04-10
KR20240148945A (ko) 2024-10-11
PL1893196T3 (pl) 2012-06-29
RS53967B1 (en) 2015-08-31
KR101332924B1 (ko) 2013-11-26
JP4644737B2 (ja) 2011-03-02
RS52274B2 (sr) 2018-05-31
CN110003114A (zh) 2019-07-12
NZ710355A (en) 2017-01-27
KR20170107585A (ko) 2017-09-25
JP2008540523A (ja) 2008-11-20
EP1893196B1 (en) 2012-01-18
NO20180225A1 (no) 2008-02-08
CA2608436C (en) 2015-03-24
EP3970721A1 (en) 2022-03-23
EP3106162A1 (en) 2016-12-21
EP2444085A1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
BE2012C042I2 (enrdf_load_html_response)
BRPI0601358B8 (pt) Aplicador de clipe cirúrgico
BRPI0601402B8 (pt) Aplicador de grampos cirúrgicos
BR122017004709A2 (enrdf_load_html_response)
BRPI0609157A8 (enrdf_load_html_response)
BRPI0608519A2 (enrdf_load_html_response)
DE602006007559D1 (enrdf_load_html_response)
AP2140A (enrdf_load_html_response)
JP2006208691A5 (enrdf_load_html_response)
JP2005270666A5 (enrdf_load_html_response)
JP2006207607A5 (enrdf_load_html_response)
BR122016029989A2 (enrdf_load_html_response)
IN2007DE09961A (enrdf_load_html_response)
BRPI0604219A (enrdf_load_html_response)
JP2005351473A5 (enrdf_load_html_response)
JP2005296015A5 (enrdf_load_html_response)
BRPI0618215B8 (enrdf_load_html_response)
JP2006283251A5 (enrdf_load_html_response)
IN2005MU01229A (enrdf_load_html_response)
JP2006256200A5 (enrdf_load_html_response)
BY2237U (enrdf_load_html_response)
CN105122969C (enrdf_load_html_response)
CN300750338S (zh) 摩托车
CN300726016S (zh) 鞋帮
CN300726008S (zh) 鞋帮